Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

RaySearch Laboratories: Year-end report 2024

Raysearch Laboratories
Download udgivelse

FOURTH QUARTER (OCTOBER - DECEMBER 2024)

  • Order intake SEK 305.0 M (317.7)
  • Net sales SEK 322.7 (299.6)
  • Operating profit SEK 73.6 M (44.4)
  • Profit after tax SEK 60.0 M (31.5)
  • Earnings per share before/after dilution SEK 1.75 (0.92)
  • Cash flow from operating activities SEK 102.9 M (115.8)
  • Order backlog SEK 1,813.2 M (1,864.4) at the end of the period.

TWELVE MONTHS (JANUARY - DECEMBER 2024)

  • Order intake SEK 1,087.2 M (1,004.2)
  • Net sales SEK 1,192.0 M (1,022.2)
  • Operating profit SEK 260.5 M (114.9)
  • Profit after tax SEK 203.5 M (81.6)
  • Earnings per share before/after dilution SEK 5.94 (2.38)
  • Cash flow from operating activities SEK 485.2 M (455.9)
  • The Board of Directors proposes a dividend for the full-year 2024 of SEK 3.00 (0.70).

SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

  • GenesisCare UK has placed an order for RayStation.
  • Number of radiotherapy clinics in China using RayStation now exceeds 100.
  • Three centers in the French Unicancer network select RayStation.
  • Institut Curie in France select RayStation for treatment planning with protons.
  • RayStation is in clinical use for proton-arc therapy at Trento Proton Therapy Center in Italy.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  • In January the Polish company Medim placed an order for the product DrugLog.
  • In October 2024, Nina Grönberg was appointed new CFO for RaySearch Laboratories AB (publ), Nina took up her position January 27.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, CEO                      Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com

Nina Grönberg, CFO              Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com

The information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 21, 2025, at 7:45 a.m.

WEBCAST

CEO Johan Löf and CFO Nina Grönberg will present RaySearch's year-end report for January-December 2024 at a webcast to be held in English on Friday, February 21, 2025 at 10:00-10:30 a.m. CET.

Link to webcast: RaySearch Year-end report 2024

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team